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1. Introduction 36 
Initial studies of renal artery sympathetic denervation as a treatment for resistant hypertension 37 
were so encouraging that they promoted investigators to launch studies to evaluate the role of 38 
this novel therapy in other conditions associated with sympathetic nervous system over 39 
activation [1-7]. For this reason, the results of the Symplicity HTN-3 trial surprised the 40 
cardiology community [8]. This trial reported that renal artery sympathetic denervation is 41 
ineffective at lowering blood pressure in patients with resistant hypertension when compared 42 
to a sham control group.  Several hypotheses have been proposed to explain these disparate 43 
results [9-12]; one possibility is that the renal sympathetic nerves were inadequately ablated, 44 
perhaps due to operator or technological factors [13]. Supporting this hypothesis, a post-hoc 45 
analysis of Symplicity HTN-3 demonstrated that those patients who had received a more 46 
comprehensive ablation procedure, i.e. a larger number of ablations and therapy to all four 47 
quadrants of each renal artery, experienced a greater reduction in blood pressure [14].  48 
 49 
Early adopters of renal denervation believed that the superior aspect of the renal artery ostium 50 
contained the greatest concentration of sympathetic nerves, and thus considered this a critical 51 
site for ablation [15]. This theory has since been dispelled by human histological data, which 52 
demonstrates that sympathetic nerves run in closer proximity to the distal rather than 53 
proximal renal artery, implying that ablation here may have a superior success rate [16]. This 54 
study also found that only 40% of renal sympathetic nerves are located within 2mm of the 55 
artery wall and it is unclear whether the first generation catheter has the capability to extend 56 
much beyond this. Newer catheters capable of creating a deeper ablation zone may target a 57 
greater proportion of sympathetic nerves and therefore be more effective [17]. 58 
 59 
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Reflecting upon these new data, future trials of renal denervation may employ a more 60 
rigorous approach, with ablations being more numerous and more distally placed, including 61 
distal to bifurcations, and targeting all four quadrants of the artery [17, 18]. Furthermore, it 62 
may be desirable to create larger ablation zones [19].  The latest second generation catheters 63 
are designed to facilitate this strategy with: 1) multiple electrode configurations that allow 64 
uniform circumferential energy delivery (Spyral™, Vessix™, EnlighHTN™ and Paradise™) 65 
[15, 20]; 2) an ability to perform ablations in arteries as narrow as 3mm in diameter 66 
(Spyral™, Vessix™), thereby enabling more distal access compared to the previous limit of 67 
4mm [21], and 3) deeper penetration into the renal adventitia (the Paradise™ system is able 68 
to create an ablation zone that extends 7-12mm from the renal artery wall) enabling 69 
attenuation of a greater proportion of the sympathetic nerves [22]. 70 
 71 
Whilst achieving adequate sympathetic nerve attenuation is clearly vital to the efficacy of the 72 
procedure, a balance must be struck with the potential risks that may be associated with an 73 
extensive ablation strategy that uses the measures outlined above [19, 23]. The purpose of 74 
this study is to explore one such risk - the potential for ‘comprehensive’ renal artery ablation 75 
to cause thermal injury to neighbouring structures. To this end, we reviewed a series of 76 
computerised tomograms (CTs) to identify those structures that lie in close proximity to the 77 
renal arteries, and which may be exposed to thermal energy using this contemporary 78 
approach. 79 
 80 
2. Methods 81 
2.1 Study Population 82 
Two experienced radiologists independently reviewed consecutive CT aortograms, obtaining 83 
a total sample size of 100 kidneys considered anatomically eligible for renal denervation. 84 
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Demographic data and relevant past medical history were collected for each patient. National 85 
Health Service (UK) Management Permission for use of anonymised patient data for research 86 
was obtained, conforming to ethical standards [24]. 87 
 88 
2.2 Renal Artery Analysis 89 
All images were acquired with a Siemens SOMATOM Definition Flash dual-source scanner, 90 
with a reconstructed slice thickness of 0.75mm [25].  Axial and coronal reconstructions were 91 
assessed for each patient thereby allowing adequate assessment of structures in both the 92 
antero-posterior and cranio-caudal axes. The arterial supply to each kidney was graded 93 
according to a modified classification [26], and the anatomic eligibility for renal denervation 94 
determined. Standard recommendations were adapted to use a renal artery diameter threshold 95 
of ≥3mm, rather than the conventional ≥4mm, thus encompassing the extended capability of 96 
some second-generation catheters. Renal arterial anatomy was categorised as follows: 97 
classically eligible (A), off-label eligible (B), or ineligible (C) (Figure 1). 98 
 99 
Only renal arteries deemed eligible for denervation (classifications A or B) were included in 100 
the study. The ‘at risk zone’ (ARZ) was defined as an area measuring 10mm (based on 101 
histology data from the Paradise™ system [22]) extending radially from the renal artery wall 102 
at any point between the ostium and the hilum, where the renal artery diameter was ≥3mm. 103 
Structures within the ARZ were documented, along with the shortest distance from the vessel 104 
wall at which these were found. In addition to this 10mm ARZ, structures within a smaller 105 
(5mm) zone were also evaluated to reflect the smaller ablation zones created by catheters 106 
with a lower maximum penetration. All measurements were rounded to the nearest mm. Any 107 
discrepancy in findings between the two observers was resolved by consensus. 108 
 109 
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2.3 Statistics 110 
Continuous variables are presented as means with standard deviations (SD). Nominal 111 
variables are presented as counts and percentages or medians with 1st and 3rd quartiles. 112 
Fisher’s exact test was used to compare categorical data. The McNemar test with the exact 113 
method was used to compare related categorical variables. All analyses were performed using 114 
SPSS (IBM version 22). 115 
 116 
3. Results 117 
Subjects had a mean age of 74.6 (SD 15.0) years and an average body mass index was 27.3 118 
(SD 5.6). 24 (48%) were male, 44 (88%) had a history of hypertension and 41 (82%) had 119 
ischaemic heart disease. 120 
 121 
Twenty-six of the 126 kidneys (63 patients) were ineligible; 18 due to renal artery stenosis, 4 122 
due to a single renal artery that was either <3mm in diameter or <20mm in length with no 123 
branch being >3mm in diameter, and 4 due to multiple ineligible renal arteries.   124 
 125 
Of the 100 eligible kidneys 73 were classically eligible for renal denervation and 27 were off-126 
label eligible; of these, 7 had a side branch measuring ≥3mm in diameter within the first 127 
20mm, 10 had multiple renal arteries each ≥3mm in diameter and ≥20mm in length prior to 128 
any bifurcation, and 10 had multiple renal arteries where at least one had a diameter ≥3mm 129 
and a length ≥20mm. 130 
 131 
In 97% of kidneys, the renal veins lie within 10mm of the renal arteries, and the inferior vena 132 
cava (IVC) is always within the ARZ of the right renal artery (Figure 2 and 3). The psoas 133 
muscles (Figure 2) and small bowel (Figure 3) are found within the ARZ in a quarter of 134 
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kidneys; however, this proportion is reduced when the smaller (5mm) zone is considered 135 
(Table 1). Neither large bowel nor renal parenchyma were found within the ARZ in any 136 
cases.  137 
 138 
The IVC and liver (Figure 4) were only encountered within the ARZ on the right, whereas the 139 
pancreas (Figure 5), adrenal gland and splenic vasculature were more commonly encountered 140 
within the ARZ on the left (Table 1). In over 50% of kidneys the renal vein and/or IVC were 141 
within 1mm of the renal artery (Table 2).  142 
 143 
Seventy-one kidneys were found to have arteries eligible for ablation before and after the first 144 
bifurcation; these are presented in Table 3. The IVC was more commonly found prior to the 145 
renal artery bifurcation whereas the psoas muscle, small bowel and liver were encountered 146 
more frequently distal to the first bifurcation (Table 3). 147 
 148 
There was no significant difference in the frequency with which structures were encountered 149 
within the ARZ when comparing classically eligible (A) to off-label eligible (B) renal 150 
arteries, and no significant difference in the frequency with which structures occurred in the 151 
ARZ for smaller diameter arteries of 3-4mm when compared with classically accepted 152 
arteries measuring ≥4mm. 153 
 154 
4. Discussion 155 
We have found that in at least one-fifth of cases the renal vein, IVC, psoas muscle or small 156 
bowel are located within 10mm of the renal artery wall and thus may inadvertently receive 157 
thermal energy during a renal denervation procedure using the latest catheters.  158 
 159 
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Manufacturers of the commercially available ablation catheters used for renal sympathetic 160 
denervation tend not to openly disclose the exact size of the ablation zones that these create; 161 
this is surprising given the large number of patients in which this procedure has been 162 
performed worldwide. A literature review found only five reports that adequately described 163 
lesion dimensions [16]. Only one of these reports was in man and describes a single patient 164 
who died from an aortic dissection several days after receiving 11 ablations with the 165 
Symplicity™ catheter [27]; on post-mortem the maximum size of the ablation zone was 166 
2mm. A study of catheter-based renal denervation in dogs using the EnligHTN™ system 167 
revealed that 90% of ablation zones did not extend beyond 3.5mm [28], and a recent study 168 
using the Symplicity™ catheter in swine found that mean distance to deepest thermal injury 169 
from the arterial lumen was 7.3mm [29]. Finally, a phantom gel model reported the mean size 170 
of ablation zones using Symplicity™ and EnligHTN™ catheters to be 3.8mm and 3.4mm 171 
respectively, although it is not possible to extrapolate the results of these studies to humans 172 
[30].  173 
 174 
The Symplicity™ catheter has been used in the majority of trials and registries to date with 175 
no reports of abdominal organ damage; this suggests that either this risk is rare and largely 176 
theoretical or it is underreported presumably as the clinical consequences of inadvertent 177 
thermal injury to the structures commonly found in the ARZ are temporary. However, several 178 
different catheter systems have since been launched, each with varying electrode 179 
configuration, energy use and biophysical properties suggesting that a class effect for neither 180 
efficacy nor safety can be assumed [15, 31]. 181 
 182 
The only available ultrasound-based system for renal denervation (Paradise™) has been 183 
shown to have a maximum penetration depth of 7-12mm in swine [22]. The development of 184 
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such powerful systems prompted us to elucidate which structures lie in the vicinity of renal 185 
arteries and thus may be affected by thermal energy.  Given our findings, that in least one-186 
fifth of eligible kidneys the renal vein, IVC, psoas muscle and small bowel are encountered 187 
within 10mm of the renal artery wall, it is interesting to note that in the animal study using 188 
the Paradise™ catheter there was evidence of small bowel necrosis and psoas muscle damage 189 
[22]. The authors of that study, based on unpublished industry data, suggested that these 190 
effects are less likely in humans due to anatomical differences between pigs and man. 191 
However, back or abdominal pain, the most commonly reported symptoms of psoas muscle 192 
and small bowel injury, have been described in up to 63% of patients following renal 193 
denervation [32]; we suggest that, if persistent, these symptoms should prompt further 194 
investigation. 195 
 196 
Another option to optimise attenuation of renal sympathetic nerves is to exploit their non-197 
uniform distribution. The nerves approximate the artery with increasing distance from the 198 
ostium (90% of sympathetic nerves are found within 9mm of the proximal main artery, 5mm 199 
of the distal main artery and 3mm of the post bifurcation artery) [16]. This implies that post-200 
bifurcation vessels may be an attractive target for denervation, particularly as a 3mm ablation 201 
zone should be achievable by most catheters. In dogs, denervation of distal branch vessels 202 
(post bifurcation) resulted in a greater reduction in renal noradrenaline concentration (the key 203 
neurotransmitter of the sympathetic nervous system [33]) than when it was performed in the 204 
main vessel only [18]. Distal vessels will generally be smaller in calibre and with the advent 205 
of the next generation catheters the minimum renal artery diameter permitted for denervation 206 
has been reduced from 4mm to 3mm. Our data suggests that this change of practice would 207 
not increase the number or frequency with which structures are encountered in close vicinity 208 
to the vessel, i.e. within the ‘at risk zone’ where they may be exposed to thermal energy.   209 
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 210 
The biophysical principles of ablation determine the effect that thermal energy has on 211 
surrounding structures. Despite the close proximity of the IVC and the renal vein to the renal 212 
artery, the risk of damage to these is low since a  high blood flow in these vessels will serve 213 
as a heat-sink [15]. The structures of greater concern are the solid organs such as bowel or 214 
liver, which do not have such protection. In our opinion, renal denervation should not be 215 
avoided in patients who on cross-sectional imaging have structures within the ARZ as 216 
currently any risk remains largely theoretical. However, we would suggest increased clinical 217 
vigilance peri-procedurally for complications within this cohort of patients.  218 
 219 
4.1 Limitations 220 
The subjects included in this study were not destined for renal denervation but instead 221 
underwent CT aortograms for other clinical indications. Patients receiving renal denervation 222 
tend to have resistant hypertension and it is conceivable with vascular remodelling that their 223 
anatomy may differ from age-matched controls.  Interestingly though, a large renal 224 
angiography study showed there to be no significant difference in anatomy between those 225 
with resistant hypertension versus non-resistant hypertension [34], and 88% of our cohort 226 
were hypertensive.  We also acknowledge the limitations of a retrospective study design, 227 
however, this should have no effect on an anatomical study. 228 
 229 
5. Conclusions 230 
Our study brings to our attention that at least one-fifth of renal arteries are in close proximity 231 
to vasculature, psoas muscle or small bowel, a finding that has not been previously reported. 232 
To date, safety has not been a significant consideration when using the first generation 233 
catheter. With the advent of more powerful catheters and a more comprehensive ablation 234 
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strategy being preferred, the same safety profile cannot be assumed. The potential risk of 235 
psoas muscle or small bowel injury suggests a possible role for cross-sectional imaging prior 236 
to renal denervation to delineate individual anatomy at risk; as yet, however, the consequence 237 
of delivering thermal energy to these structures remains uncertain. 238 
 239 
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Figure Legends 245 
 246 
Figure 1: Classification of eligibility for renal denervation based on renal artery 247 
anatomy. 248 
 249 
Figure 2: Axial computerised tomogram showing the close proximity of the right renal 250 
artery (white arrow), the right renal vein (RV) and the psoas muscles (PM). 251 
 252 
Figure 3: Axial computerised tomogram showing the close proximity of the right renal 253 
artery (white arrow) and the inferior vena cava (IV) and the left renal artery (black 254 
arrow) and small bowel (SB). 255 
 256 
Figure 4: Axial computerised tomogram showing the close proximity of the right renal 257 
artery (white arrow) and the liver (L). 258 
 259 
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Figure 5: Axial computerised tomogram showing the close proximity of the left renal 260 
artery (white arrow) and the pancreas (P). 261 
262 
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Table 1: The frequency with which structures are encountered within 10mm and 5mm of the renal artery, comparing right with left. 
 
Structures within 10 or 
5mm of the renal 
artery 
10mm 5mm 10mm vs 5mm 
Right 
Renal 
Artery 
(n=51) 
Left 
Renal 
Artery 
(n=49) 
Total 
(n=100) 
R vs L 
P 
(Fisher’s) 
Right 
Renal 
Artery 
(n=51) 
Left 
Renal 
Artery 
(n=49) 
Total 
(n=100) 
R vs L 
P 
(Fishers’s) 
P (McNemar’s) 
Renal Vein 50 (98%) 47 (96%) 97 (97%) 0.614 48 (94%) 42 (86%) 90 (90%) 0.196 0.016 
IVC 51 (100%) 0 (0%) 51 (51%) <0.001 51 (100%) 0 (0%) 51 (51%) <0.001 1.000 
Psoas Muscles 14 (28%) 11 (22%) 25 (25%) 0.647 10 (17%) 8 (16%) 18 (18%) 0.796 0.016 
Small Bowel 13 (26%) 12 (25%) 25 (25%) 1.000 7 (14%) 4 (8%) 11 (11%) 0.526 <0.001 
Pancreas 2 (4%) 8 (16%) 10 (10%) 0.049 1 (2%) 6 (12%) 7 (7%) 0.057 0.250 
Liver 8 (16%) 0 (0%) 8 (8%) 0.006 3 (6%)  0 (0%) 3 (3%) 0.243 0.063 
Adrenal 0 (0%) 7 (14%) 7 (7%) 0.005 0 (0%) 5 (10%) 5 (5%) 0.025 0.500 
Diaphragm 3 (6%) 2 (4%) 5 (5%) 1.000 2 (4%) 1 (2%) 3 (3%) 1.000 0.500 
Splenic Artery 0 (0%) 3 (6%) 3 (3%) 0.114 0 (0%) 2 (4%) 2 (2%) 0.238 0.500 
Table 1
Splenic Vein 0 (0%) 1 (2%) 1 (1%) 0.490 0 (0%) 0 (0%) 0 (0%)  0.500 
 
 
Table 2: Median distance between structure and renal artery wall, quartile 1 (Q1), and 
quartile 3 (Q3). 
 
 
Median distance (Q1, 
Q3), mm 
Renal Vein 1 (0, 2) 
IVC 0 (0, 1) 
Psoas Muscles 4 (3, 6) 
Small Bowel 6 (3.5, 7) 
Pancreas 5 (1, 6.3) 
Liver 6.5 (4.3, 7.8) 
Adrenal 3 (2, 6) 
Diaphragm 4 (2.5, 9) 
Splenic Artery 5 (3, 8) 
Splenic Vein 7 (7,7) 
 
Table 2
Table 3: Frequency with which structures are encountered within 10mm and 5mm of 
the renal artery wall before and after the first bifurcation. P values are from 
McNemar’s test. 
Structures 
10mm 5mm 
Pre-
Bifurcation 
(n=71) 
Post-
Bifurcation 
(n=71) P  
Pre-
Bifurcation 
(n=71) 
Post-
Bifurcation 
(n=71) P  
Renal Vein 63 55 0.115 59 53 0.286 
IVC 35 12 <0.001 35 11 <0.001 
Psoas Muscles 5 17 0.004 4 15 0.003 
Small Bowel 5 15 0.041 2 8 0.109 
Liver 1 8 0.016 1 3 0.500 
Pancreas 3 6 0.250 2 6 0.125 
Adrenal 4 2 0.625 3 1 0.625 
Diaphragm 4 1 0.250 2 1 1.000 
Splenic Artery 1 1 1.000 0 1 1.000 
Splenic Vein 1 0 1.000 0 0  
 
 
Table 3
